Back

Murine osteosarcoma recapitulates the driver landscape and genomic complexity of osteosarcoma evolution in humans

Smith, G. A.; van Belzen, I. A. E. M.; Epinette, M.; Herdes, E.; Mercer, K. L.; Butterworth, C. G.; Rust, A. G.; Flanagan, A. M.; Jones, M. G.; Cortes-Ciriano, I.; Jacks, T.

2026-04-28 cancer biology
10.64898/2026.04.27.721100 bioRxiv
Show abstract

Osteosarcoma (OS) genomes are characterized by complex genomic rearrangements (CGRs) that drive genomic instability and clonal diversification early in tumor evolution. As a result, OS tumors display high inter-patient variability, which has hindered molecular stratification and targeted therapeutic development. To study genomic complexity in OS and credential a genetically engineered mouse model of the disease (Sp7-Cre Trp53fl Rb1fl), we performed high-depth and multi-region whole genome sequencing (WGS) of 35 tumor samples from 24 mice. Similar to human OS, the murine OS tumors (mOS) had a high number of somatic structural variants (158 per tumor) with low tumor mutational burden of single nucleotide variants (0.87 mutations/MB). CGRs were identified in 63% (15/24) of mOS cases, most frequently affecting chromosome 15 (33%, 8/24 mice) and resulting in Myc amplification in 6 mice, ranging from 5 to 104 copies. Myc amplification was verified with DNA FISH, long-read sequencing and gene expression data, which revealed examples of Myc amplification in both extrachromosomal circular DNA (ecDNA) and in derivative chromosomes generated by CGRs. PTEN loss occurred frequently (59% 12/22 mice), and contributed to osteosarcomagenesis, as demonstrated by tumor initiation with in vivo CRISPR/Cas9-mediated deletion experiments (2 mice). Together, these results demonstrate that a preclinical model of osteosarcoma can generate the genomic heterogeneity and complexity of the human disease, thereby facilitating research into mechanisms of tumor initiation and drivers of progression and relapse.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Cancer Research
116 papers in training set
Top 0.1%
14.5%
2
eLife
5422 papers in training set
Top 9%
8.3%
3
Nature Communications
4913 papers in training set
Top 30%
6.3%
4
Oncogene
76 papers in training set
Top 0.4%
4.2%
5
Molecular Cancer Research
42 papers in training set
Top 0.1%
3.9%
6
Clinical Cancer Research
58 papers in training set
Top 0.4%
3.9%
7
Cancer Discovery
61 papers in training set
Top 0.5%
3.9%
8
Journal of Bone and Mineral Research
32 papers in training set
Top 0.1%
3.6%
9
JBMR Plus
16 papers in training set
Top 0.1%
2.8%
50% of probability mass above
10
Cell Reports
1338 papers in training set
Top 18%
2.7%
11
Cancers
200 papers in training set
Top 2%
2.0%
12
JCI Insight
241 papers in training set
Top 3%
1.9%
13
Communications Biology
886 papers in training set
Top 7%
1.9%
14
Genome Medicine
154 papers in training set
Top 5%
1.7%
15
Cell Reports Medicine
140 papers in training set
Top 4%
1.7%
16
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 33%
1.7%
17
Science Translational Medicine
111 papers in training set
Top 3%
1.6%
18
Disease Models & Mechanisms
119 papers in training set
Top 1%
1.5%
19
Science
429 papers in training set
Top 16%
1.3%
20
Science Advances
1098 papers in training set
Top 22%
1.3%
21
Leukemia
39 papers in training set
Top 0.6%
1.2%
22
Genes & Development
90 papers in training set
Top 0.8%
1.2%
23
Journal of Clinical Investigation
164 papers in training set
Top 4%
1.2%
24
Bone
22 papers in training set
Top 0.3%
1.2%
25
Cell Genomics
162 papers in training set
Top 5%
1.2%
26
Developmental Cell
168 papers in training set
Top 10%
0.9%
27
Molecular Cancer Therapeutics
33 papers in training set
Top 0.5%
0.9%
28
Blood
67 papers in training set
Top 1%
0.9%
29
npj Precision Oncology
48 papers in training set
Top 1%
0.9%
30
Frontiers in Oncology
95 papers in training set
Top 4%
0.7%